04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
07:00 , Apr 14, 2016 |  BC Innovations  |  Strategy

Next stop: Houston

Last month's opening by Johnson & Johnson of the Houston-based JLABS incubator is being seen as a coup by local leaders hoping to make the city the "third coast" of biotech. But stakeholders inside and...
08:00 , Feb 5, 2015 |  BC Innovations  |  Finance

PPPs holding steady

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...
07:00 , Mar 20, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Beta Cat Pharmaceuticals, CerRx, DNAtrix, Essa Pharma, ProNAi, ProPep Surgical, Cancer Prevention and Research Institute of Texas cancer news

The institute awarded three-year grants totaling up to $63.2 million to six cancer companies based in or relocating to Texas. The institute also awarded $22.9 million for 11 research grants for academic projects and research...